Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2024-11-19 Board/Management Inform…
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Board Committee Change
Board/Management Information Classification · 1% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service), indicated by the RNS Number and the closing boilerplate text referencing RNS and the London Stock Exchange. The core content announces a 'Board Committee Change,' specifically that Gian Piero Reverberi is stepping down from the Board Audit Committee. This type of announcement, detailing changes in the composition of the board or senior management, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter is MANG, which takes precedence over the general RNS category.
2024-11-19 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document explicitly states its subject matter is 'Transaction in Own Shares' and details the purchase of ordinary shares by the company (Syncona Limited) as part of a 'share buyback programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the closing statement referencing RNS as the Primary Information Provider confirms it is a regulatory announcement, but the specific content dictates the POS classification over the general RNS fallback.
2024-11-19 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document explicitly states the subject is 'Transaction in Own Shares' and details the purchase of 450,000 Ordinary Shares as part of a 'share buyback programme'. It provides specific transaction details (date, price, volume) and updates the total voting rights following the treasury share acquisition. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the closing statement about RNS confirms it is a regulatory announcement, but the specific content dictates the POS classification over the general RNS fallback.
2024-11-18 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document explicitly states the subject is "Transaction in Own Shares" and details the purchase of Ordinary Shares by the Company as part of a "share buyback programme." It provides the date of purchase, the number of shares purchased, and the weighted average price. This directly corresponds to the definition of a Transaction in Own Shares (share repurchase/issuance), which maps to the filing code POS. The presence of the RNS Number and the LSE distribution boilerplate confirms it is a regulatory announcement, but the specific content dictates the most precise classification.
2024-11-15 English
Syncona launches Slingshot Therapeutics
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 1663M' and contains standard regulatory boilerplate language at the end, referencing 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content announces the launch of a new portfolio company ('Slingshot') by Syncona, detailing initial funding (£12.5 million) and strategic focus. This is a general, time-sensitive announcement made via the Regulatory News Service (RNS). Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), the most appropriate classification for a general regulatory announcement distributed via RNS is 'Regulatory Filings' (RNS). The document length (7256 chars) is substantial enough that it is not merely a placeholder for a report, but the announcement itself.
2024-11-14 English
Half-year Report
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Results' announcement for Syncona Limited for the six months ended 30 September 2024. It contains substantive financial data, including net asset value (NAV), portfolio valuations, and detailed financial performance metrics. While it is an announcement, it provides the actual interim financial results rather than just a notice of publication, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.